Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Flucavex
- Development stage
- Unknown
- Lead developer
- Pharma Bavaria International
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Flucavex is a fixed-dose combination of paracetamol (acetaminophen), pheniramine maleate, and ascorbic acid (vitamin C), formulated as granules for oral solution. Developed by Pharma Bavaria International, it is approved for the symptomatic treatment of common colds, rhinitis, rhinopharyngitis, and flu-like symptoms in adults and adolescents over 15 years of age. Paracetamol acts as an analgesic and antipyretic by inhibiting prostaglandin synthesis in the central nervous system. Pheniramine maleate is a first-generation antihistamine that acts as an inverse agonist at the histamine H1 receptor, reducing symptoms such as rhinorrhea, sneezing, and watery eyes. Ascorbic acid is included to help meet the increased physiological demand for vitamin C during infections. Flucavex is administered orally after dissolving the granules in water.
- Brand names
- Flucavex
- Other names
- acetaminophen + ascorbic acid + pheniramine maleateascorbic acid + acetaminophen + pheniramine maleateascorbic acid + paracetamol + pheniramine maleateparacetamol + pheniramine + ascorbic acidparacetamol + pheniramine maleate + ascorbic acid
02
Targets
HRH1 (Histamine H1 Receptor)PGHS-1 (Prostaglandin G/H Synthase 1)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)
Beyond the preview
Go deeper on Flucavex.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Flucavex.